1. AB0088 The role of high mobility group box-1 (HMGB1) in inflammatory vasculopathy in collagen antibody-induced arthritis (CAIA). (15th June 2017) Authors: Biscetti, F; Flex, A; Angelini, F; Gremese, E; Tolusso, B; Ferraccioli, G Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1077 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Allele *2 of the HS1, 2A enhancer of the Ig regulatory region associates with rheumatoid arthritis. Issue 3 (24th October 2008) Authors: Tolusso, B; Frezza, D; Mattioli, C; Fedele, A L; Bosello, S; Faustini, F; Peluso, G; Giambra, V; Pietrapertosa, D; Morelli, A; Gremese, E; De Santis, M; Ferraccioli, G F Journal: Annals of the rheumatic diseases Issue: Volume 68:Issue 3(2009) Page Start: 416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. (June 2017) Authors: Carbonella, A; Mancano, G; Gremese, E; Alkuraya, F S; Patel, N; Gurrieri, F; Ferraccioli, G Journal: Lupus Issue: Volume 26:Number 7(2017) Page Start: 768 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Autoantibodies and thrombophilia in RA: TNFα and TNFα blockers. Issue 6 (17th March 2004) Authors: Ferraccioli, G F; Gremese, E Journal: Annals of the rheumatic diseases Issue: Volume 63:Issue 6(2004) Page Start: 613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. B cell activating factor (BAFF) and BAFF receptors: fakes and facts. (28th September 2017) Authors: Ferraccioli, G; Gremese, E Journal: Clinical and experimental immunology Issue: Volume 190:Number 3(2017:Dec.) Page Start: 291 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. (2nd February 2018) Authors: Alivernini, S; Tolusso, B; Ferraccioli, G; Gremese, E; Kurowska-Stolarska, M; McInnes, I B Journal: Clinical and experimental immunology Issue: Volume 193:Number 1(2018:Jul.) Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FRI0143 Prevalence and determinants of peripheral endothelial dysfunction in a cohort of rheumatoid arthritis patients: preliminary results from a multicenter cross-sectional study. (15th June 2017) Authors: Erre, GL; Piga, M; Fedele, AL; Cadoni, ML; Sante, G Di; Cangemi, I; Piras, A; Dessì, M; Mura, S; Tolusso, B; Longu, MG; Saba, PS; Gremese, E; Cauli, A; Ferraccioli, G; Mathieu, A; Passiu, G Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 535 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FRI0319 Predictors of complete remission in polymyalgia rheumatica. (15th June 2017) Authors: Birra, D; Zoli, A; Peluso, G; Bosello, SL; Gremese, E; Ferraccioli, G Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 608 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. (3rd September 2018) Authors: Fedele, AL; Petricca, L; Tolusso, B; Alivernini, S; Canestri, S; Di Mario, C; Bosello, SL; Ferraccioli, G; Gremese, E Journal: Scandinavian journal of rheumatology Issue: Volume 47:Number 5(2018) Page Start: 351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. OP0015 Induction of remission and maintenance in early, aggressive rheumatoid arthritis using adalimumab in combination with methotrexate with or without short-term high-dose glucocorticoids: results of a phase iv multicenter, randomized, double blind study (clintrial.gov: NCT00480272). (15th June 2017) Authors: Caporali, R; Montecucco, C; Bocci, E Bartoloni; Vitolo, B; Prisco, E; Klersy, C; Giacomelli, R; Triolo, G; Cutolo, M; Marchesoni, A; Gremese, E; Iannuccelli, C; Tirri, R; Grassi, W; Lopalco, G; Galeazzi, M; Cerinic, M Matucci; Punzi, L; Ferraccioli, G Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗